Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma

BACKGROUND. Vemurafenib has been approved for the treatment of patients with advanced BRAF(V600E)-mutant melanoma. This report by the Vemurafenib Dermatology Working Group presents the characteristics of dermatologic adverse events (AEs) that occur in vemurafenib-treated patients, including cutaneou...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Lacouture, Mario E., Duvic, Madeleine, Hauschild, Axel, Prieto, Victor G., Robert, Caroline, Schadendorf, Dirk, Kim, Caroline C., McCormack, Christopher J., Myskowski, Patricia L., Spleiss, Olivia, Trunzer, Kerstin, Su, Fei, Nelson, Betty, Nolop, Keith B., Grippo, Joseph F., Lee, Richard J., Klimek, Matthew J., Troy, James L., Joe, Andrew K.
Formato: Artigo
Lenguaje:Inglês
Publicado: AlphaMed Press 2013
Materias:
Melanoma and Cutaneous Malignancies
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3607529/
https://ncbi.nlm.nih.gov/pubmed/23457002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0333
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares